

---

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**SCHEDULE 13D**

Under the Securities Exchange Act of 1934

**(Amendment No. 3)\***

**WEREWOLF THERAPEUTICS, INC.**

---

**(Name of Issuer)**

**Common Stock**

---

**(Title of Class of Securities)**

**95075A107**

---

**(CUSIP Number)**

**Ansbert Gadicke**  
**c/o MPM BioImpact LLC, 339 Boylston Street, Suite 1100**  
**Boston, MA, 02116**  
**617-425-9200**

---

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)**

**12/01/2025**

---

**(Date of Event Which Requires Filing of This Statement)**

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

**SCHEDULE 13D**

**CUSIP No. 95075A107**

Name of reporting person

1

MPM BioVentures 2014, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE  
Sole Voting Power

7 2,111,105.00  
Number of Shares Beneficially Owned by Each Reporting Person With:  
8 Shared Voting Power  
0.00  
9 Sole Dispositive Power  
2,111,105.00  
10 Shared Dispositive Power  
0.00  
Aggregate amount beneficially owned by each reporting person

11 2,111,105.00  
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13 4.3 %  
Type of Reporting Person (See Instructions)

14 PN

## SCHEDULE 13D

**CUSIP No.** 95075A107

1 Name of reporting person  
MPM BioVentures 2014 (B), L.P.  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE  
7 Sole Voting Power

Number of

Shares	
Beneficially	140,807.00
Owned by	Shared Voting Power
Each	8
Reporting	0.00
Person	Sole Dispositive Power
With:	9
	140,807.00
	Shared Dispositive Power
	10
	0.00
	Aggregate amount beneficially owned by each reporting person
11	140,807.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	<input type="checkbox"/>
	Percent of class represented by amount in Row (11)
13	0.3 %
	Type of Reporting Person (See Instructions)
14	PN

## SCHEDULE 13D

**CUSIP No.** 95075A107

1	Name of reporting person
	MPM Asset Management Investors BV2014 LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	SEC use only
	Source of funds (See Instructions)
4	WC
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	<input type="checkbox"/>
	Citizenship or place of organization
6	DELAWARE
	Sole Voting Power
7	72,664.00
Number of	Shared Voting Power
Shares	8
Beneficially	0.00
Owned by	Sole Dispositive Power
Each	9
Reporting	72,664.00
Person	Shared Dispositive Power
With:	10
	0.00
11	Aggregate amount beneficially owned by each reporting person

72,664.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

0.1 %

Type of Reporting Person (See Instructions)

14

OO

## SCHEDULE 13D

**CUSIP No.** 95075A107

Name of reporting person

1

UBS Oncology Impact Fund L.P.

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

CAYMAN ISLANDS

Sole Voting Power

7

1,745,647.00

Number of  
Shares

Shared Voting Power

Beneficially  
Owned by

8

0.00

Each  
Reporting

9

Sole Dispositive Power

Person  
With:

1,745,647.00

Shared Dispositive Power

10

0.00

Aggregate amount beneficially owned by each reporting person

11

1,745,647.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

3.6 %

Type of Reporting Person (See Instructions)

14

PN

# SCHEDULE 13D

**CUSIP No.** 95075A107

1 Name of reporting person  
MPM BioVentures 2014 GP LLC  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE

7 Sole Voting Power  
0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

8 Shared Voting Power  
2,251,912.00

9 Sole Dispositive Power  
0.00

10 Shared Dispositive Power  
2,251,912.00

11 Aggregate amount beneficially owned by each reporting person  
2,251,912.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13   
Percent of class represented by amount in Row (11)  
4.6 %

14 Type of Reporting Person (See Instructions)  
OO

# SCHEDULE 13D

**CUSIP No.** 95075A107

1 Name of reporting person  
MPM BioVentures 2014 LLC  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE

7 Sole Voting Power

Number of Shares Beneficially Owned by Each Reporting Person With: 8 0.00  
Shared Voting Power 2,324,576.00  
9 Sole Dispositive Power 0.00  
10 Shared Dispositive Power 2,324,576.00  
Aggregate amount beneficially owned by each reporting person

11 2,324,576.00  
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13 4.8 %  
Type of Reporting Person (See Instructions)

14 OO

## SCHEDULE 13D

**CUSIP No.** 95075A107

1 Name of reporting person  
Oncology Impact Fund (Cayman) Management L.P.  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 CAYMAN ISLANDS

Number of Shares Beneficially 7 Sole Voting Power 0.00

Owned by Each Reporting Person With:	8	Shared Voting Power
		1,745,647.00
		Sole Dispositive Power
	9	0.00
		Shared Dispositive Power
	10	1,745,647.00
11	Aggregate amount beneficially owned by each reporting person	
		1,745,647.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)	
		<input type="checkbox"/>
13	Percent of class represented by amount in Row (11)	
		3.6 %
14	Type of Reporting Person (See Instructions)	
		PN

## SCHEDULE 13D

**CUSIP No.** 95075A107

1	Name of reporting person	
	MPM BioImpact LLC	
	Check the appropriate box if a member of a Group (See Instructions)	
2	<input type="checkbox"/>	(a)
	<input checked="" type="checkbox"/>	(b)
3	SEC use only	
4	Source of funds (See Instructions)	
	WC	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
	<input type="checkbox"/>	
6	Citizenship or place of organization	
	DELAWARE	
		Sole Voting Power
	7	0.00
		Shared Voting Power
Number of Shares Beneficially Owned by Each Reporting Person With:	8	1,745,647.00
		Sole Dispositive Power
	9	0.00
		Shared Dispositive Power
	10	1,745,647.00
11	Aggregate amount beneficially owned by each reporting person	
		1,745,647.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)	

Percent of class represented by amount in Row (11)  
13 3.6 %  
Type of Reporting Person (See Instructions)  
14 OO

## SCHEDULE 13D

**CUSIP No.** 95075A107

1 Name of reporting person  
ANSBERT GADICKE  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 UNITED STATES

	Sole Voting Power
7	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
8	4,867,341.00
	Sole Dispositive Power
9	0.00
	Shared Dispositive Power
10	4,867,341.00

Aggregate amount beneficially owned by each reporting person

11 4,867,341.00  
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13 10.0 %  
Type of Reporting Person (See Instructions)

14 IN

## SCHEDULE 13D

1 Name of reporting person  
LUKE EVNIN  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 UNITED STATES  
Sole Voting Power

7 0.00  
Number of Shares Beneficially Owned by Each Reporting Person With:  
8 Shared Voting Power  
3,121,694.00  
9 Sole Dispositive Power  
0.00  
10 Shared Dispositive Power  
3,121,694.00  
Aggregate amount beneficially owned by each reporting person

11 3,121,694.00  
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13 6.4 %  
Type of Reporting Person (See Instructions)

14 IN

SCHEDULE 13D

1 Name of reporting person  
Todd Foley  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

UNITED STATES

Sole Voting Power

7

0.00

Number of  
Shares

Shared Voting Power

Beneficially

8

Owned by

2,324,576.00

Each

Sole Dispositive Power

Reporting

9

Person

0.00

With:

Shared Dispositive Power

10

2,324,576.00

Aggregate amount beneficially owned by each reporting person

11

2,324,576.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

4.8 %

Type of Reporting Person (See Instructions)

14

IN

## SCHEDULE 13D

**CUSIP No.** 95075A107

Name of reporting person

1

MPM ASSET MANAGEMENT LLC

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

DELAWARE

Sole Voting Power

7

334,302.00

Number of  
Shares

Beneficially

Owned by

8

Shared Voting Power

Each

Reporting Person	0.00
With:	Sole Dispositive Power
	9
	334,302.00
	Shared Dispositive Power
	10
	0.00
	Aggregate amount beneficially owned by each reporting person
11	334,302.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	<input type="checkbox"/>
	Percent of class represented by amount in Row (11)
13	0.7 %
	Type of Reporting Person (See Instructions)
14	OO

## SCHEDULE 13D

**CUSIP No.** 95075A107

1	Name of reporting person
	MPM ONCOLOGY INNOVATIONS FUND LP
	Check the appropriate box if a member of a Group (See Instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	SEC use only
	Source of funds (See Instructions)
4	WC
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	<input type="checkbox"/>
	Citizenship or place of organization
6	DELAWARE
	Sole Voting Power
	7
	462,816.00
Number of Shares Beneficially Owned by Each Reporting Person	Shared Voting Power
With:	8
	0.00
	Sole Dispositive Power
	9
	462,816.00
	Shared Dispositive Power
	10
	0.00
	Aggregate amount beneficially owned by each reporting person
11	462,816.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	<input type="checkbox"/>

13 Percent of class represented by amount in Row (11)

1.0 %

Type of Reporting Person (See Instructions)

14

PN

## SCHEDULE 13D

**CUSIP No.** 95075A107

Name of reporting person

1

MPM Oncology Innovations Fund GP LLC

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

DELAWARE

Sole Voting Power

7

0.00

Number of  
Shares

Shared Voting Power

Beneficially 8

Owned by

462,816.00

Each

Sole Dispositive Power

Reporting 9

Person

0.00

With:

Shared Dispositive Power

10

462,816.00

Aggregate amount beneficially owned by each reporting person

11

462,816.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

1.0 %

Type of Reporting Person (See Instructions)

14

OO

## SCHEDULE 13D

Item 1. Security and Issuer

(a) Title of Class of Securities:

Common Stock

Name of Issuer:

(b) WEREWOLF THERAPEUTICS, INC.

Address of Issuer's Principal Executive Offices:

(c) 200 TALCOTT AVENUE, 2ND FLOOR, WATERTOWN, MASSACHUSETTS , 02472.

**Item 1 Explanatory Note:** This Amendment No. 3 to Schedule 13D ("Amendment No. 3") is being filed as an amendment to the initial statement on Schedule 13D relating to the common stock (the "Common Stock"), of Werewolf Therapeutics Inc. (the 'Issuer'), as filed with the Securities and Exchange Commission (the "SEC") on May 14, 2021 and as amended by Amendment No. 1 filed November 4, 2025 and Amendment No. 2 filed November 17, 2025 (as amended, the "Original Schedule 13D"). This Schedule 13D/A is being filed by the Filing Persons to report the open market sales of the Issuer's Common Stock by certain Filing Persons. Items 5 and 7 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment No. 3 but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

See rows (11) and (13) of the Filing Persons Owner Profile of this Amendment No. 3 for the aggregate number of Common Stock and percentages of the shares of Common Stock beneficially owned by the Filing Person. The Common Stock is held as follows: \* 2,111,105 shares are held directly by BV 2014; \* 140,807 shares are held directly by BV 2014(B); \* 72,664 shares are held directly by AM BV2014 LLC; \* 462,816 shares are held directly by MPM OIF; \* 334,302 shares by AM LLC; and \* 1,745,647 shares are held directly by UBS Oncology. BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B) and, accordingly, may be deemed to beneficially own the shares held by BV 2014 and BV 2014(B). BV 2014 LLC is the managing member of AM BV2014 LLC and, accordingly, may be deemed to beneficially own the shares held by AM BV2014 LLC. MPM OIF GP is the general Partner of MPM OIF and, accordingly, may be deemed to beneficially own the shares held by MPM OIF. BioImpact and Oncology Cayman are the direct and indirect general partners of UBS Oncology and, accordingly, may be deemed to beneficially own the shares held by UBS Oncology. Drs. Gadick and Evnin and Mr. Foley are the managing directors of BV 2014 LLC and, accordingly, may be deemed to beneficially own the shares held by BV 2014, BV 2014(B) and AM BV2014 LLC. Drs. Gadick and Evnin are the members of AM LLC and managers of MPM OIF GP and, accordingly, may be deemed to beneficially own the shares held by AM LLC and MPM OIF. Dr. Gadick is the managing partner of BioImpact and, accordingly may be deemed to beneficially own the shares held by UBS Oncology. Calculation of the percentage of the shares of Common Stock beneficially owned is based upon 48,540,200 Common Stock outstanding as of October 29, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on November 4, 2025.

(a) See rows (7) through (10) of the Filing Persons Owner Profile of this Amendment No. 3 for the number of shares as to which there is sole power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition.

The Reporting Persons sold the following Common Stock in the open market since the date of filing Amendment No. 2: Date of Price Range Ave. Price Sold by Sold by Sold By Sold by Sold by Sale BV 2014 BV 2014(B) AM BV2014 MPM OIF AM LLC UBS Oncology LLC 11/18/25 \$0.8902-\$0.9601 \$0.93 22,827 1,523 786 5,027 3,613 18,851 11/19/25 \$0.901-\$0.9806 \$0.94 28,768 1,919 990 6,335 4,554 23,758 11/20/25 \$0.8506-\$0.9556 \$0.89 17,850 1,191 614 3,931 2,825 14,741 11/21/25 \$0.80-\$0.8861 \$0.83 27,904 1,861 960 6,145 4,417 23,044 11/24/25 \$0.8733-\$1.03 \$0.98 38,518 2,569 1,325 8,483 6,097 31,810 11/25/25 \$0.90-\$0.99 \$0.92 18,449 1,230 635 4,063 2,920 15,236 11/26/25 \$0.9328-\$1.01 \$0.98 26,343 1,757 907 5,801 4,170 21,755 11/28/25 \$0.9681-\$1.01 \$0.99 8,795 587 303 1,937 1,392 7,263 12/01/25 \$0.905-\$1.00 \$0.94 26,423 1,762 910 5,819 4,182 21,821 12/02/25 \$0.852-\$0.9246 \$0.89 25,712 1,715 884 5,662 4,070 21,234 12/03/25 \$0.82-\$0.9256 \$0.87 24,821 1,656 854 5,466 3,929 20,499

(d) Inapplicable.

(e) Inapplicable.

**Item 7. Material to be Filed as Exhibits.**

Joint Filing Statement

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

MPM BioVentures 2014, L.P.

Signature: /s/ Ansbert Gadick

Name/Title: Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM

BioVentures 2014 GP LLC, the General Partner of  
MPM BioVentures 2014, L.P.

Date: 12/03/2025

MPM BioVentures 2014 (B), L.P.

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Director of MPM BioVentures 2014  
LLC, Managing Member of MPM BioVentures  
2014 GP LLC, the General Partner of MPM  
BioVentures 2014 (B), L.P.

Date: 12/03/2025

MPM Asset Management Investors BV2014 LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Director of MPM BioVentures 2014  
LLC, the manager of MPM Asset Management  
Investors BV2014 LLC

Date: 12/03/2025

UBS Oncology Impact Fund L.P.

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Partner of MPM BioImpact LLC, the  
GP of Oncology Impact Fund (Cayman)  
Management L.P., the GP of UBS Oncology  
Impact Fund L.P.

Date: 12/03/2025

MPM BioVentures 2014 GP LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Director of MPM BioVentures 2014  
LLC, the Managing Member of MPM  
BioVentures 2014 GP LLC

Date: 12/03/2025

MPM BioVentures 2014 LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Director

Date: 12/03/2025

Oncology Impact Fund (Cayman) Management L.P.

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Partner of MPM BioImpact LLC, the  
General Partner of Oncology Impact Fund  
(Cayman) Management L.P.

Date: 12/03/2025

MPM BioImpact LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Partner

Date: 12/03/2025

ANSBERT GADICKE

Signature: /s/ Ansbert Gadicke

Name/Title: Ansbert Gadicke

Date: 12/03/2025

LUKE EVNIN

Signature: /s/ Luke Evnin

Name/Title: Luke Evnin

Date: 12/03/2025

Todd Foley

Signature: /s/ Todd Foley

Name/Title: Todd Foley

Date: 12/03/2025

MPM ASSET MANAGEMENT LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Member

Date: 12/03/2025

MPM ONCOLOGY INNOVATIONS FUND LP

Signature: /s/ Ansbert Gadicke

Manager of MPM Oncology Innovations Fund GP  
Name/Title: LLC, the General Partner of MPM Oncology  
Innovations Fund, L.P.

Date: 12/03/2025

MPM Oncology Innovations Fund GP LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Manager

Date: 12/03/2025

## Joint Filing Statement

I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Werewolf Therapeutics, Inc. is filed on behalf of each of the undersigned.

Date: December 3, 2025

### **MPM BioVentures 2014, L.P.**

By: MPM BioVentures 2014 GP LLC,  
its General Partner

By: MPM BioVentures 2014 LLC,  
Its Managing Member

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Managing Director

### **MPM BioVentures 2014 (B), L.P.**

By: MPM BioVentures 2014 GP LLC,  
its General Partner

By: MPM BioVentures 2014 LLC,  
Its Managing Member

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Managing Director

### **MPM Asset Management Investors BV 2014 LLC**

By: MPM BioVentures 2014 LLC  
Its: Manager

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Managing Director

### **MPM BioVentures 2014 GP, LLC**

By: MPM BioVentures 2014 LLC,  
Its Managing Member

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Managing Director

---

**MPM BioVentures 2014 LLC**

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Managing Director

**MPM Asset Management LLC**

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Member

**MPM Oncology Innovations Fund LP**

By: MPM Oncology Innovations Fund GP LLC  
its General Partner

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Manager

**MPM Oncology Innovations Fund GP LLC**

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Manager

**UBS Oncology Impact Fund, L.P.**

By: Oncology Impact Fund (Cayman) Management L.P.,  
its General Partner  
By: MPM BioImpact LLC,  
Its General Partner

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Managing Partner

---

**Oncology Impact Fund (Cayman) Management L.P.**

By: MPM BioImpact LLC,  
Its General Partner

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Managing Partner

**MPM BioImpact LLC**

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Managing Partner

By: /s/ Todd Foley  
Name: Todd Foley

By: /s/ Luke Evnin  
Name: Luke Evnin

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke